DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 3, 2014, Pages 646-656

  Klaus, Christine R ^a   Iwanowicz, Dorothy ^a   Johnston, Danielle ^a   Campbell, Carly A ^a   Smith, Jesse J ^a   Moyer, Mikel P ^a   Copeland, Robert A ^a   Olhava, Edward J ^a   Scott, Margaret Porter ^a   Pollock, Roy M ^a   Daigle, Scott R ^a   Raimondi, Alejandra ^a  

^a EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DIFLUORO 2 PHENETHYLPHENYL)CYCLOPROPANAMINE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; AZACITIDINE; BROMODOMAIN INHIBITOR; CYTARABINE; DAUNORUBICIN; DECITABINE; ENZYME INHIBITOR; IBET 151; MAFOSFAMIDE; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; PANOBINOSTAT; PINOMETOSTAT; PREDNISOLONE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT; 2 (6 AMINO 9H PURIN 9 YL) 5 [[[3 [2 (5 TERT BUTYL 1H BENZIMIDAZOL 2 YL)ETHYL]CYCLOBUTYL](ISOPROPYL)AMINO]METHYL]TETRAHYDROFURAN 3,4 DIOL; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DOT1L PROTEIN, HUMAN; EPZ-5676; GROWTH INHIBITOR; METHYLTRANSFERASE;

ACUTE LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL SPECIFICITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL LINE; MOLM 13 CELL LINE; MV4 11 CELL LINE; PRIORITY JOURNAL; SKM 1 CELL LINE; ACUTE GRANULOCYTIC LEUKEMIA; CELL PROLIFERATION; DRUG EFFECT; METABOLISM; METHYLATION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; GROWTH INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; METHYLATION; METHYLTRANSFERASES;

EID: 84907291965     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214577     Document Type: Article

References (46)

1. Arrowsmith CH, Bountra C, Fish PV, Lee K, and Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11:384-400.
2. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, and Dworzak MN, et al. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114:2489-2496.
3. Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, and Scott MP, et al. (2012) Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 80:971-980.
4. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, and Bullinger L, et al. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20:66-78.
5. Bhojwani D, Howard SC, and Pui CH (2009) High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma 9 (Suppl 3):S222-S230 10.3816/CLM.2009.s.016.
6. Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KS, Allis CD, and Roeder RG (2011) Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci USA 108:15751-15756.
7. Bitoun E, Oliver PL, and Davies KE (2007) The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 16:92-106.
8. Bruserud O, Gjertsen BT, and Huang Ts (2000) Induction of differentiation and apoptosis- a possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist 5:454-462.
9. Burnett A, Wetzler M, and Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487-494.
10. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, and Watson MS, et al.; Cancer and Leukemia Group B (CALGB 8461) (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336.
11. Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, Gozani O, Kutateladze TG, and Cleary ML (2010) Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J Mol Biol 400:137-144.
12. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, and Pollock RM, et al. (2013) Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27:813-822.
13. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681.
14. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, and Scott MP, et al. (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122:1017-1025.
15. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, and Xiao Y, et al. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53-65.
16. Deshpande AJ, Bradner J, and Armstrong SA (2012) Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol 33:563-570.
17. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, and Daigle SR, et al. (2013) Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121:2533-2541.
18. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, Croce CM, Nakamura T, Canaani E, and Young RA (2008) Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev 22:3403-3408.
19. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674.
20. Hess JL (2004) MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 10:500-507.
21. Inaba H, Greaves M, and Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet 381:1943-1955.
22. Jabbour E, Cortes J, Ravandi F, O'Brien S, and Kantarjian H (2013) Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 50:271-283.
23. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, and Feliu JB, et al. (2014) Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 20:2226-2235 10.1158/1078-0432.CCR-13-1978.
24. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705.
25. Krivtsov AV and Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823-833.
26. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, and Silverman LB, et al. (2008) H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14:355-368.
27. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, and Hess JL (2002) MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10:1107-1117.
28. Milne TA, Martin ME, Brock HW, Slany RK, and Hess JL (2005) Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res 65:11367-11374.
29. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, Washburn MP, Florens L, and Shilatifard A (2010) Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 24:574-589.
30. Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, Slany RK, and Hess JL (2011) MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol 39:77-86, e1-e5.
31. Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KW, Strout MP, Hutchison RE, Moore JO, and Mayer RJ, et al. (1997) Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 90:4532-4538.
32. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, and Hess JL, et al. (2007) A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110:4445-4454.
33. Mueller D, García-Cuéllar MP, Bach C, Buhl S, Maethner E, and Slany RK (2009) Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 7:e1000249.
34. Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R, Dubois G, Mazo A, Croce CM, and Canaani E (2002) ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10:1119-1128.
35. Neff T and Armstrong SA (2013) Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood 121:4847-4853.
36. Nguyen AT, Taranova O, He J, and Zhang Y (2011) DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117:6912-6922.
37. Nowak D, Stewart D, and Koeffler HP (2009) Differentiation therapy of leukemia: 3 decades of development. Blood 113:3655-3665.
38. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, and Zhang Y (2005) hDOT1L links histone methylation to leukemogenesis. Cell 121:167-178.
39. Park G, Gong Z, Chen J, and Kim JE (2010) Characterization of the DOT1L network: implications of diverse roles for DOT1L. Protein J 29:213-223.
40. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, and Aminova O, et al. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366:1079-1089.
41. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, and Ferster A, et al. (2007) A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370:240-250.
42. Slany RK (2009) The molecular biology of mixed lineage leukemia. Haematologica 94:984-993.
43. Tamai H and Inokuchi K (2010) 11q23/MLL acute leukemia : update of clinical aspects. J Clin Exp Hematop 50:91-98.
44. Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, Zhang H, Liu Z, Ernst P, and Koretzky GA, et al. (2010) MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17:148-159.
45. Yokoyama A, Lin M, Naresh A, Kitabayashi I, and Cleary ML (2010) A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17:198-212.
46. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, and Yi J, et al. (2012) Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 3:1288.